Home › Female Infertility › NCT03496636
Autologous Ovarian Tissue Transplantation
Who can join
Ages 18 to 45 · Women
Full eligibility criteria
Inclusion Criteria: * Previously cryopreserved ovarian tissue * Ovarian insufficiency and/or candidate for pregnancy * Good health * Oncologist's clearance Exclusion Criteria: * Patients considered to be high risk for surgical complications * Women with contraindication for pregnancy if goal is to achieve pregnancy * Women positive for the BRCA mutations * Women with a history of leukemia, ovarian cancer or a cancer that likely involved ovaries at the time of ovarian tissue collection * Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent * Current pregnancy
About the study
Chemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO08050491). The objective of this study is to study the efficacy and safety of autologous tissue transplantation in patients diagnosed with primary ovarian insufficiency after chemotherapy and/or radiation treatments.
What is being tested
- Ovarian tissue transplant (procedure)
Sponsor: University of Pittsburgh · Participants: 5 · Started: Mar 1, 2021
Contact the study team
- Jennifer Anglin · Phone: 412-641-7475
Official record on ClinicalTrials.gov — NCT03496636
Locations in the U.S.
| Pennsylvania | Magee-Womens Hospital, Pittsburgh |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.